OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen

NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html

Syndivia receives the EU’s Horizon 2020 grant

The European Commission has named Syndivia as one of the new Phase 1 beneficiaries of the European Union's SME Instrument. SME Instrument is a highly competitive grant that supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument Phase 1 grant is aimed to fund the feasibility assessment of Syndivia's next-generation targeted cancer therapies.

flag-yellow-low.jpg

Job opening announcement | Research Assistant in Mass Spectrometry

Syndivia is looking for a highly motivated candidate for a PhD project on characterisation of antibody-drug conjugates by mass spectrometry.
The responsibilities of the candidate will include:

  • Development of high-throughput analytical methods for determination of drug-to antibody ratio (DAR)
  • Identification of conjugation sites in site-specific and classical antibody-drug conjugates
  • Collaborating with outside groups on project-related studies.


An ideal candidate will have knowledge and experience in:

  • Native mass spectrometry
  • Proteomics


Please, send your CV, a motivation letter and names of two referees to enquiry@syndivia.com

Syndivia signs distribution agreement with Sigma-Aldrich

Syndivia has signed a distribution agreement with Sigma-Aldrich. Following this agreement, Syndivia’s proprietary bioconjugation reagents are now available in the catalog of Sigma-Aldrich. For the complete list of products visit: http://www.sigmaaldrich.com/catalog/search?term=apn

“It is our priority to provide the research community with the cutting-edge tools for bioconjugation. Commercialization of APN reagents is an important step for advancing therapeutic and diagnostic applications of bioconjugates” – commented Oleksandr Koniev, Syndivia’s CEO.

3128791.png

Meet us at the SMi's annual ADC Summit

May 23-24, Syndivia's CEO will be giving a talk at the SMi's annual ADC Summit in London.
The topics covered in the talk will include:
•    New ADC linkers with increased serum stability
•    Next-generation DM1- and MMAE-based payloads
•    Expanding the scope of ADC targets by fine-tuning the drug release properties
For more information, visit the website of the conference:
https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summit
 

Publication in Bioconjugate Chemistry

Syndivia introduces a first-in-class reagent for kinetically resolved thiol-to-thiol conjugation in its recent publication in Bioconjugate Chemistry. The MAPN reagent allows for the preparation of stable Antibody-Drug Conjugates through conjugation of thiol-containing drugs to the cysteine residues of the antibody.
The publication can be downloaded on the ACS website: http://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.5b00440

1970467.png

Syndivia is among the TOP 100 SMEs of the Hello Tomorrow Challenge

Syndivia is selected as one of the TOP100 startups of the Hello Tomorrow Challenge, placing it in the top 3% of the projects participating in the contest.

Hello Tomorrow Challenge is a global competition of tech-startups with more than 3600 participants spread across 6 major tech fields: Energy & Environment, Information Technologies, Food & Agriculture, Healthcare, Materials & Manufacturing, and Transport & Mobility.

4925767.png

Syndivia is granted the prestigious MATWIN label

Following the final presentation in front of the International Board of MATWIN, the project ADC 2.0, presented by Syndivia, was granted the MATWIN label and the prize in the category of "Best Challenging Project". The prestigious MATWIN label rewards high-quality projects with strong potential in the area of oncology.
MATWIN (Maturation & Accelerating Translation With INdustry) is a nationwide service platform which is unique in Europe and which supports the maturation of research projects in oncology, up to the pre-clinical proof of concept.

3854579.jpg